shutterstock_1587802498_nitpicker
nitpicker / Shutterstock.com
29 June 2021AmericasMuireann Bolger

Flatwing fails to shift attorney fees to Pfizer unit, Anacor

Generic drug maker Flatwing Pharmaceuticals has lost its bid to offset nearly $690,000 in fees and expenses to Pfizer unit Anacor Pharmaceuticals after a US federal judge ruled that the “circumstances were not exceptional” enough to warrant the shift.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
1 September 2020   Anacor Pharmaceuticals has unsuccessfully challenged the invalidation of four patents covering Kerydin, an antifungal treatment for nails.
Americas
18 May 2016   Pfizer has announced that it will be buying Anacor Pharmaceuticals for $5.2 billion, which will lead to it adding an experimental treatment for eczema, called Crisaborole, to its portfolio.

More on this story

Americas
1 September 2020   Anacor Pharmaceuticals has unsuccessfully challenged the invalidation of four patents covering Kerydin, an antifungal treatment for nails.
Americas
18 May 2016   Pfizer has announced that it will be buying Anacor Pharmaceuticals for $5.2 billion, which will lead to it adding an experimental treatment for eczema, called Crisaborole, to its portfolio.

More on this story

Americas
1 September 2020   Anacor Pharmaceuticals has unsuccessfully challenged the invalidation of four patents covering Kerydin, an antifungal treatment for nails.
Americas
18 May 2016   Pfizer has announced that it will be buying Anacor Pharmaceuticals for $5.2 billion, which will lead to it adding an experimental treatment for eczema, called Crisaborole, to its portfolio.